A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066/ABBV-066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naive to, or Were Previously Treated With Anti-TNF Therapy

Trial Profile

A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066/ABBV-066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naive to, or Were Previously Treated With Anti-TNF Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Crohn's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AbbVie; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 09 May 2017 Results assesing the efficacy and safety of open-label subcutaneous risankizumab maintenance therapy (n=62) at week 52, presented at the Digestive Disease Week 2017.
    • 12 Apr 2017 Results published in the LANCET.
    • 29 Nov 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top